Epidermal inflammation pathways

The term "epidermal inflammation pathways" does not refer to a discrete, canonical molecule or receptor, but rather to a collection of molecular mechanisms and signaling cascades that mediate inflammatory responses in the skin's outermost layer, the epidermis. These pathways include multiple interconnected molecular actors: immune cell-derived cytokines (notably IL-17, IL-4, IL-13, TNF-α), activation of transcription factors (such as NF-κB, HIF-1α, and aryl hydrocarbon receptor/AHR), metabolic regulators (e.g., mTOR), and pattern recognition receptors (PRRs) involved in detecting pathogens and tissue damage. In inflammatory skin diseases such as psoriasis and atopic dermatitis, dysregulation of these pathways leads to excessive immune cell infiltration, aberrant keratinocyte activation, impaired skin barrier function, increased cytokine production, and sustained inflammation. Targeting components of these pathways is an established strategy in dermatology, and interventions often focus on specific cytokines or transcription factors, not the general pathway ensemble itself. Since "epidermal inflammation pathways" is a category describing complex biological systems rather than a single, druggable biomolecule, it is not considered a therapeutic target in the strict sense, and is likely too broad or non-specific to serve as a valid entry for structured drug target databases.

Other names

Epidermal inflammation pathwaysEpidermal inflammatory pathwaysSkin inflammatory signaling pathwaysCutaneous inflammatory cascades

Cytokine pathway inhibition, Transcription factor modulation, Metabolic pathway modulation, Barrier function restoration